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BACKGROUND: In the search for prognostic biomarkers, a significant amount of precious biobanked blood
samples is needed for conventional analyses. Solid-phase proximity ligation assay (SP-PLA) is an analytic method
with the ability to analyze many proteins at the same time in small amounts of plasma. The aim of this study was to
explore the potential use of SP-PLA for biomarker validation in patients with colorectal cancer (CRC). MATERIAL
AND METHODS: Plasma samples from patients with stage I to IV CRC, with (n = 31) and without (n = 29) disease
dissemination at diagnosis or later, were analyzed with SP-PLA using 35 antibodies targeting an equal number of
proteins in 5-μl plasma samples. Carcinoembryonic antigen (CEA), analyzed earlier in this cohort using a different
technology, was used as a reference. RESULTS: A total of 21 of the 35 investigated proteins were detectable with
SP-PLA. Patients in stage II to III with disseminated disease had lower plasma concentrations of HCC-4 (P = .025).
Low plasma levels of tissue inhibitor of metalloproteinases–1 were seen in patients with disseminated disease
stage II (P = .003). The level of CEA was higher in patients with disease dissemination compared with those
without (P = .007). CONCLUSION: SP-PLA has the ability to analyze many protein markers simultaneously in a
small amount of blood. However, none of the markers selected for the present SP-PLA analyses gave better
prognostic information than CEA.
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Tumor markers in colorectal cancer (CRC) have the potential to play
a crucial role in screening, prognostication, and therapeutic
monitoring. Carcinoembryonic antigen (CEA) is the most known
and widely used marker. Because of its low sensitivity for identifying
individuals with CRC, CEA is not recommended for screening [1].
Even though CEA has low sensitivity, it is the only marker certificated
for detection of early recurrence, although many patients with tumor
relapse have normal CEA levels [2].
Earlier survival analyses in the present CRC cohort revealed that
patients with stage I disease have no risk of developing tumor
recurrence for up to 5 years, although the 5-year overall survival (OS)
was only 75% due to death from other diseases. In CRC stage II, only
14% developed cancer recurrence, and the 5-year OS was similar to
stage I or 74%. In CRC stage III, 40% developed disease recurrence,
and the 5-year OS was 54% [3]. For stage III CRC patients, adjuvant
treatment improves OS by 15% to 20%, whereas 60% are alreadycured by the primary surgery alone [4]. The use of adjuvant therapy is
not routinely recommended for patients with CRC stage II, but for
groups at high risk for recurrence like those with T4, emergency
surgery and analysis of a few lymph nodes may be offered treatment,
although the benefits are not well proven [5].
It would certainly be of great benefit to find biomarkers that could
identify those 14% of stage II and 40% with stage III CRC who will
have cancer recurrence. This could radically change the strategy of
Table 1. Comparison of Clinicopathological Characteristics in Patients with and without Disease
Dissemination
Characteristics No Dissemination (n = 29) Dissemination (n = 31) P Value
Age (years)
Median (range) 76 (49-91) 69 (34-85) NS
Gender
Female 13 18 NS
Male 16 13
Localization
Right/left colon 14/15 9/22 NS
Colon/rectum 20/9 19/12
Disease stage
I 8 1 *
II 12 10
III 9 10
IV - 10
Differentiation
Well-moderate 26 25 NS
Poor 3 9
Mucinous
Yes 3 4 NS
No 26 26
Vascular invasion
Yes 0 5 NS
No 29 25
Neural invasion
Yes 0 2 NS
No 29 28
CEA
b6 ng/ml 24 15 .007
≥6 ng/ml 5 16
* Not relevant testing due to strategic selection of patients.
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treatment with all its side effects and improving the surveillance of
those at higher risk of tumor recurrence.
The proximity ligation assay (PLA) is a recently described protein
detection assay. Pairs of oligonucleotide-labeled antibodies (PLA-probes)
are used to detect the target antigen.When two such PLA-probes bind the
same antigen, the probes are brought in proximity, leading to formation
of a template DNA strand by ligation. The DNA strand is then amplified
by quantitative real-time polymerase chain reaction to detectable signals
[6]. Solid- phase PLA (SP-PLA) is a form of PLA where antibodies
immobilized on a solid support act as capture agents for the target proteins
before the PLA [7]. There are several advantages in detecting plasma
biomarkers using PLA, such as increased specificity, minimal sample
consumption, and the capacity to simultaneously analyze numerous
targets in a multiplex format [8].
The primary aim of this study was to explore the use of SP-PLA to
evaluate the concentrations of a set of potential biomarkers in clinical
plasma samples from patients with CRC according to disease stage
and recurrence in relation to CEA. For this purpose, a strategic sample
of a limited number of patients was selected.
Material and Methods
Sixty patients from a previously described cohort of 320 patients [9],
operated for CRC at the Central District Hospital, Västerås, County
of Västmanland, were strategically selected. Nine patients had disease
stage I, one of whom had a recurrence after 7 years. Twenty-two
patients had stage II disease, 10 of whom had a recurrence; 19 had
stage III disease, with 9 having a recurrence; and 10 patients were at
stage IV at diagnosis. Patients were divided into two groups: those
with disease dissemination (stage I-III with recurrence and stage IV)
and those without dissemination (stage I-III without recurrence). The
purpose was to select approximately 10 patients each with stage I,
stage II with/without dissemination, stage III with/without dissem-
ination, and stage IV. Among patients with nondisseminated disease,
six received postoperative adjuvant chemotherapy of which all were in
stage III of the disease. The patients were treated between August
2000 and December 2003. Information about stage, localization,
differentiation, and vascular and neural invasion was received from
pathology records. Information on death and cancer recurrence was
received from surgical and oncology records and from the Clinical
Database for Colorectal Cancer held at the Regional Oncologic
Centre in Uppsala/Örebro.
Preoperative collection of blood samples was drawn into EDTA
tubes and processed for plasma by centrifugation. The samples have
been stored in −70°C for at least 10 years before being analyzed.
Methods
SP-PLA. From each patient, 5 μl of plasma was used for protein
detection with multiplex SP-PLA, as described by Darmanis [6,7].
The multiplex protein detection panel was preselected by the science
group of U Landegren for explorative studies and comprised 35
proteins previously reported as biomarkers for cancer, inflammation,
or cardiovascular disease, and 1 internal control (mouse IgG) [6]. For
each protein in the panel, individual dilutions of recombinant
proteins were prepared at high, medium, or low concentrations
(1 nM, 10 pM, and 0.1 pM, total volume of 45 μl). Quantification of
each protein was made by real-time polymerase chain reaction of the
DNA reporter strands that formed in the detection reactions. Molar
protein concentrations were converted to pg/μl before analysis.Statistical Analyses
The χ2 and Fisher’s exact tests were used for comparisons of
categorical variables. The Mann-Whitney U test was used to compare
the plasma levels of selected biomarkers and dissemination status and
between each disease stage. Kruskal-Wallis test was used to compare
values of plasma levels biomarkers and stage of the disease.
Statistical significance was set at P b .05. All observations were
censored at the end of the study period (15th April 2010).
SPSS statistics version 21 (SPSS Inc., Chicago, IL) was used for
statistical analysis.
Ethical approval (number 2000:001) was obtained from the Ethics
Committee at Uppsala University, Uppsala, Sweden.
Results
Patient Characteristics
Of 60 patients, 65% had colon cancer; and 35%, rectal cancer.
Thirty-one patients had disseminated disease, and 29 were without
dissemination. The median age of patients with dissemination was 69
years (range, 34-85), and for patients with nondisseminated disease, it
was 76 years (range, 49-91) (Table 1). There were no statistically
significant differences in age, gender, tumor localization, tumor
differentiation, and presence of vascular and neural invasion between
the two groups. The cases with vascular or neural invasion were,
however, confined to the disseminated group. Patients with disease
dissemination had higher CEA levels than those without (P = .007)
(Table 1), which could also be seen when comparing the disease stages
(P = .040) (Table 2).
Plasma Analyses of Detectable Biomarkers
The plasma level of 35 biomarkers (Table 3), of which 21 were
detectable, and also including one internal control were analyzed with
Table 2. Comparison of Preoperatively Taken CEA between Disease Stages I and IV CRC
Disease Stage CEA b6 ng/ml CEA ≥6 ng/ml P Value
I 8 1 .040
II 14 8
III 14 5
IV 3 7
Table 4.Descriptive Value of Detectable Biomarkers Plasma Levels (pM/μl) Analyzed with SP-PLA
in CRC Patients Stages I to IV
Biomarkers 1st Quartile 2nd Quartile 3ed Quartile Min Value Max Value
TIMP1 2951.58 3281. 14 3767.52 2083.76 6254.69
VEGF 3.12 4.39 5.81 1.66 21.71
E-Selectin 242.36 395.93 547.36 81.08 1437.95
Cystatin C 14,138.27 15,761.99 18,358.41 9828.02 27,761.97
Cathepsin B 8161.66 10,054.53 11,968.79 5220.28 20,118.34
IL-8 1.69 2.26 2.98 0.99 155.63
CF3 14.58 18.44 26.23 5.82 856.83
ICAM-1 2408.89 2888.55 3470.66 1671.87 6862.89
Cathepsin S 385.41 430.31 549.40 191.09 1126.73
CCL2 24.53 32.11 41.51 13.77 123.99
CCL4 15.74 21.46 31.87 5.20 145.89
Fas 53.13 70.23 102.14 24.75 637.96
CCL5 1839.26 2095.30 2316.75 1019.98 4372.21
Follistatin 18.08 24.51 30.60 1.21 73.95
CXCL5 37.18 54.84 72.92 11.41 422.44
HCC-4 1381.14 1489.09 1670.85 407.89 2379.58
IL17a 1.34 1.89 2.64 0.81 38.67
P-selectin 897.43 1273.11 1706.64 499.77 10,369.68
TIMP4 184.90 249.85 408.40 77.99 1485.46
Kallikrein 6 131.06 149.93 177.50 79.34 1002.89
GDF15 71.54 124.95 258.40 22.69 1008.22
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descriptive results for the detectable biomarkers.
Plasma concentrations of detectable biomarkers in patients with
disease stage I to 1V CRC revealed no statistically significant
differences between the different stages. Neither were any significant
differences seen when analyzing the relations to disease dissemination
(data not shown). Patients with disseminated disease stage II to III did
have lower median plasma concentration of 1 out of the 21 detectable
markers, the “cancer marker” HCC-4, compared with those with no
dissemination (P = .025) (Table 5, Figure 1). Low plasma levels of
tissue inhibitor of metalloproteinases (TIMP)–1 were also seen in
patients with disseminated disease stage II (P = .003, Figure 2). The
patients with disseminated disease tended to be younger than those
with nondisseminated disease (median age, 68 and 79 years,
respectively) (data not shown). We could not detect any significant
relation between age and TIMP-1 plasma levels (data not shown).
Discussion
SP-PLA has the potential to become an important tool in the search
for new prognostic biomarkers. With only a few microliters necessary
for the analysis of, as in our case, 35 different proteins, it enables
efficient use of limited, often precious biobanked serum or plasma
samples in search for new biomarkers in CRC. This work was a pilot
study and the first to test the multiplex SP-PLA method on a clinical
series of cancer patients. A strategic selection of cases was done to
maximize the chances to obtain potentially clinically valuableTable 3. Detectable and Nondetectable Proteins Analyzed with SP-PLA in Patients with CRC
Biomarkers Detectable (n = 21)
Markers for inflammation Interleukin 8 (IL8)
Interleukin 17A (IL17A)
Vascular endothelial growth
Markers for cardiovascular disease Growth differentiation facto
Intercellular adhesion molec
P-selectin
E-selectin
Chemokine (C-C) ligand 2 (
Cystatin C
Coagulation factor III (CF3)
Markers for cancer Chemokine (C-XC) ligand 5
Kallikrein 6
Chemokine (C-C) ligand 16
Tissue inhibitor of metallopr
Tissue inhibitor of metallopr
Follistatin
Chemokine (C-C) ligand 4 (
Chemokine (C-C) ligand 5 (
Cathepsin B
Cathepsin S
Fas
Internal control Mouse Ig Ginformation from a limited number of samples. Nonetheless, the
small sample size provides insufficient power for statistical analysis,
which makes it difficult to draw definitive conclusions regarding
relations between plasma level of biomarkers and disease dissemina-
tion. It is still reasonable to conclude that none of the analyzed
markers will have a future clinical value in separating stages and
disseminated cases of CRC. The two findings that achieve statistical
significance may well be a reflection of multiple testing, presenting
many opportunities for isolated observation below the probability
threshold we have applied because great number of comparisons were
done. We found low plasma levels of HCC-4 in patients with
disseminated disease stage II-III. It has been described that HCC4,
also known as CCL16, LEC, LCC1, NCC4, LMC, exertsNondetectable (n = 14)
Interleukin 7 (IL7)
Interleukin 6 (IL6
factor (VEGF) Interleukin 4 (IL4)
Interleukin 10 (IL10)
Interleukin 1alpha (IL1α)
Tumor necrosis factor alpha (TNF-α)
r 15 (GDF-15) CD40 ligand
ule 1 (ICAM-1) Cystatin B
CCL2)
(CXCL5) Epidermal growth factor (EGF)
Growth hormone
(HCC-4) Artemin
oteinase 1 (TIMP-1) p53
oteinase 4 (TIMP-4) PSA
Nerve growth factor beta (NGF-β)
CCL4)
CCL5)
Figure 2. Plasma levels of TIMP-1 in patients with CRC stage II,
with and without dissemination.
Table 5. Comparison in Median Value of Detectable Biomarker’s Plasma Levels in Patients with
Disseminated or Nondisseminated CRC, Disease Stage II to III
Biomarkers Dissemination,
Stage II to III (n = 20)
Nondissemination,
Stage II to III (n = 21)
P Value
TIMP-1 3136.75 3324.83 NS
VEGF 4.33 5.45 NS
E-Selectin 271.15 343.12 NS
Cystatin C 15,923.75 15,248.01 NS
Cathepsin B 10,048.99 9863.31 NS
IL-8 2.23 2.14 NS
CF3 16.60 17.21 NS
ICAM-1 2575.66 2713.22 NS
Cathepsin S 421.78 452.24 NS
CCL2 29.51 21.01 NS
CCL4 19.57 22.54 NS
Fas 73.44 82.72 NS
CCL5 2101.09 2051.12 NS
Follistatin 24.39 26.02 NS
CXCL5 54.25 53.84 NS
HCC-4 1428.29 1527.38 .025
IL17a 1.96 1.60 NS
P-selectin 1183.69 1149.97 NS
TIMP-4 278.40 261.90 NS
Kallikrein 6 159.76 158.57 NS
GDF15 133.71 115.84 NS
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impaired tumour cell growth in a mouse adenocarcinoma cell
line [11].
Tissue inhibitor of metalloproteinases is involved in cancer
progression and could be used as a selective marker for metastatic
disease, especially TIMP-1 [12]. Our study failed to corroborate a
significant relationship between high plasma levels of TIMP-1 and
disease dissemination. Contrary to what would be expected, patients
in stage II disseminated disease had lower average TIMP-1 plasma
levels. Patients in stage II with dissemination tended to be younger
than those without disease dissemination. It has been shown that
TIMP-1 plasma levels increase with age [12]. Birgisson et al. showed
that patients in stage III with high TIMP-1 levels not receiving
adjuvant chemotherapy had the highest risk of recurrence [12]. Our
inability to confirm this herein is likely a problem of power for our
study design.Figure 1. Plasma levels of HCC-4 in patients with and without
dissemination, stages II to III CRC. The boxes represent quartiles
and medians, and bars minimum and maximum. Asterisks are
extremes and circles are outliers.The outcome of the study necessarily also depends on the selection
of biomarkers to be tested. The majority of the selected biomarkers
with some roles in cancer, inflammation, and cardiovascular pathways
were detectable with SP-PLA in the samples. Several inflammatory
proteins are described to have important roles in tumor biology.
Overexpression of IL-8 has been linked to upregulation of matrix
metalloproteinases, a group of proteins with roles in cancer
progression and metastasis [13]. Our multiplex panel includes several
proteins that have previously been described to have prognostic value
in CRC [14,15]. Angiogenesis plays an important role in tumor
growth and metastasis. The marker protein VEGF included in our
panel is involved in regulation of both normal and tumor
angiogenesis, and by binding to its receptor, cell proliferation and
vascularization are induced [16]. Bevacizumab is an anti-VEGF
monoclonal antibody used as additional treatment in patients with
metastatic CRC [17].
Preoperatively taken CEA was the marker exhibiting highest
significance among the investigated individuals. Increased plasma
levels correlated with increasing stage and with disseminated disease as
opposed to localized disease. CEA is routinely taken as a gold standard
marker, although its clinical value in patients with primary CRC is
limited. It was reassuring that the levels correlated with both stage and
the presence of tumor dissemination, whether known (stage IV) or
occult (stage II+III with recurrence), despite the limited number of
patients. Herein CEA was not measured using multiplex SP-PLA
because the biomarkers were already preselected. In the clinical
setting, tumor–lymph node–metastasis staging system is the most
precise prognostic factor in therapeutic decision making. Few, if any,
biomarkers have been convincingly shown to offer more accurate
prediction of prognosis in combination with tumor–lymph node–
metastasis staging. CEA is the most widely used protein biomarker in
CRC and considered as an independent prognostic marker, especially
in patients with stage II CRC and for monitoring therapy in advanced
disease [18,19]. Regular measurement of CEA in patients with
curatively resected CRC is recommended, and Figueredo et al. also
showed that CEA testing and/or liver imaging improves the survival
rate [20].
Enzyme-linked immunosorbent assay is today the gold standard
method for plasma protein detection; however, SP-PLA uses only a
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cross-reactivity and high sensitivity [8]. Other than plasma and
serum, SP-PLA can be applied in whole blood, cerebrospinal fluid,
brain homogenates, and tissue and cell lysates [7]. Darmanis et al.
used SP-PLA to investigate the same preselected proteins as used
herein in plasma samples from patients with cardiovascular disease
compared with matched controls. The study revealed three
potentially relevant diagnostic markers for cardiovascular disease
[6]. The authors concluded that the technique could provide a
platform for validation of diagnostic biomarkers both in biobanked
samples and for clinical use [6]. Wallin et al. used multiplex SP-PLA
to show that patients with CRC and high levels of the protein
GDF-15 in tumor tissues had shorter time to recurrence and reduced
overall survival [21]. In that study, plasma levels of GDF-15 were
reported for the same 60 patients as used herein. The plasma levels
correlated weakly with CEA levels, but as also reported here, no
correlations were seen with stage and dissemination.
The present work represents one of the first to test the SP-PLA
method on plasma from patients with CRC, and the interpretation of
the results must be taken with some caution. The method is rapidly
developing, and analyses of up to 92 proteins and 4 internal controls
at the same time are now possible using SP-PLA or a variant of the
technique: proximity extension assays [22]. Simultaneous analyses of
large sets of proteins require appropriate study design to avoid risks of
chance findings due to the multiple variables being tested.
In conclusion, SP-PLA is a suitable method for detecting and
validating prognostic and predictive biomarkers. Because CRC is a
heterogeneous disease, understanding its molecular pathogenesis can
offer enormous advantages in clinical decision making with important
treatment implications; herein, multiplex SP-PLA might give valuable
guidance in pursuing new biomarkers.
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